Renalytix Plc (RNLXY)
OTCMKTS · Delayed Price · Currency is USD
0.2400
-0.0150 (-5.88%)
Oct 22, 2025, 4:00 PM EDT
Renalytix Market Cap
Renalytix has a market cap or net worth of $37.55 million as of October 22, 2025. Its market cap has increased by 131.23% in one year.
Market Cap
37.55M
Enterprise Value
36.03M
Revenue
2.89M
Ranking
n/a
PE Ratio
n/a
Stock Price
$0.24
Market Cap Chart
Since November 6, 2018, Renalytix's market cap has decreased from 84.47M to 37.55M, a decrease of -55.55%. That is a compound annual growth rate of -10.99%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Oct 22, 2025 | 37.55M | -15.77% |
| Dec 31, 2024 | 44.57M | 125.93% |
| Dec 29, 2023 | 19.73M | -69.84% |
| Dec 30, 2022 | 65.42M | -89.22% |
| Dec 31, 2021 | 607.05M | 26.62% |
| Dec 31, 2020 | 479.42M | 67.37% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Nov 6, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Veradigm | 804.99M |
| Elite Pharmaceuticals | 644.08M |
| Glass House Brands | 624.73M |
| Silence Therapeutics | 349.53M |
| Nika Pharmaceuticals | 335.28M |
| CytoDyn | 326.28M |
| Northwest Biotherapeutics | 324.50M |
| American Oncology Network | 289.95M |